Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types

Monoclonal gammopathy of uncertain significance (MGUS) is the requisite precursor to multiple myeloma (MM), a malignancy of antibody‐producing plasma B‐cells. The genetic basis of MGUS and its progression to MM remains poorly understood. C57BL/KaLwRij (KaLwRij) is a spontaneously derived inbred mouse strain with a high frequency of benign idiopathic paraproteinemia (BIP), a phenotype with similarities to MGUS including progression to MM. Using mouse haplotype analysis, human MM SNP array data, and whole exome and whole genome sequencing of KaLwRij mice, we identified novel KaLwRij gene variants, including deletion of Samsn1 and deleterious point mutations in Tnfrsf22 and Tnfrsf23. These variants significantly affected multiple cell types implicated in MM pathogenesis including B‐cells, macrophages, and bone marrow stromal cells. These data demonstrate that multiple cell types contribute to MM development prior to the acquisition of somatic driver mutations in KaLwRij mice, and suggest that MM may an inherently non‐cell autonomous malignancy.

[1]  Thomas W. Mühleisen,et al.  Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. , 2014, Blood.

[2]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[3]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[4]  R. Kyle,et al.  Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. , 2011, Blood.

[5]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[6]  S. Beer-Hammer,et al.  Immunoinhibitory Adapter Protein Src Homology Domain 3 Lymphocyte Protein 2 (SLy2) Regulates Actin Dynamics and B Cell Spreading* , 2011, The Journal of Biological Chemistry.

[7]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[8]  Arthur S Slutsky,et al.  Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1 , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  Rafael Fonseca,et al.  Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.

[10]  Allan S. Brett,et al.  Prevalence of Monoclonal Gammopathy of Undetermined Significance , 2006 .

[11]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[12]  R. Hoover,et al.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. , 2005, Blood.

[13]  A. Zallone,et al.  T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. , 2004, Blood.

[14]  Yuan-Xiao Zhu,et al.  The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades , 2004, The Journal of experimental medicine.

[15]  Gonzalez,et al.  Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.

[16]  H. V. van Vlijmen,et al.  Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)* , 2003, The Journal of Biological Chemistry.

[17]  Yuan-Xiao Zhu,et al.  HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells , 2001, Oncogene.

[18]  G. Mundy,et al.  A murine model of human myeloma bone disease. , 1997, Bone.

[19]  J. Radl,et al.  Idiopathic paraproteinaemia. I. Studies in an animal model--the ageing C57BL/KaLwRij mouse. , 1978, Clinical and experimental immunology.

[20]  J. Epstein,et al.  The SCID-hu myeloma model. , 2005, Methods in molecular medicine.

[21]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..